Positive Two-Year Data from the ALPS Registry of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System
The ALPS Registry is a multi-center, retrospective study conducted at centers in Alkmaar, Netherlands; Leipzig, Germany; Paris; and Singapore encompassing 32 end-stage – or “no-option” – CLTI patients.
March 12, 2020 In this video, watch as Dr. Roberto Ferraresi, Cardiologist, Humanitas University and Director, Interventional Peripheral Unit, Humanitas Gavazzeni (Bergamo, Italy), Dr. Daniel G. Clair, Professor of Surgery, the University of South Carolina and Chairman, Department...
The successful first case was performed by Mark Archie, MD, principal investigator for the PROMISE II trial at Harbor-UCLA Medical Center, and Nina Bowens, MD, sub-investigator for the PROMISE II trial at Harbor-UCLA Medical Center.
LimbFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study
LimbFlow reports this clinical trial is the initial step towards a U.S. approval pathway for the LimFlow System.
LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients
When all other therapeutic options have been exhausted and a CLI patient is facing major amputation, the minimally-invasive LimFlow system is designed to bypass blocked arteries in the leg and rush oxygenated blood back into the foot.